A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

NCT05683457 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Cytomegalovirus Infection

Interventions

BIOLOGICAL: mRNA-1647
BIOLOGICAL: Placebo

Sponsor

ModernaTX, Inc.